A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care

NCT02598011 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Newly Diagnosed High Grade Glioma (HGG)

Interventions

BIOLOGICAL: Toca 511
DRUG: Toca FC

Sponsor

Tocagen Inc.